Oncolytic Viruses as Reliable Adjuvants in CAR-T Cell Therapy for Solid Tumors.

ABSTRACT: Although impactful scientific advancements have recently been made in cancer therapy, there remains an opportunity for future improvements. Immunotherapy is perhaps one of the most cutting-edge categories of therapies demonstrating potential in the clinical setting. Genetically engineered T cells express chimeric antigen receptors (CARs), which can detect signals expressed by the molecules present on the surface of cancer cells, also called tumor-associated antigens (TAAs). Their effectiveness has been extensively demonstrated in hematological cancers; therefore, these results can establish the groundwork for their applications on a wide range of requirements. However, the application of CAR-T cell technology for solid tumors has several challenges, such as the existence of an immune-suppr

SUBMITTER: Stilpeanu RI 

PROVIDER: S-EPMC11508774 | biostudies-literature | 2024 Oct

REPOSITORIES: biostudies-literature